Karyopharm Therapeutics Inc. [KPTI] saw a change by -4.57% with the Thursday trading session, closing the trade at the price of $15.34. The company is holding 62.61M shares with keeping 51.51M floating shares. With the latest trading session, the stock is set at 291.20% off compared to its 52-week low, sliding -23.67% from high for the same period of time.
Since its 90-day high, the share price saw a move by -23.59%, trading +2.06% in oppose to its 90-day low While during the day, 62.61M shares valued at 901837 were bought and sold.
Karyopharm Therapeutics Inc. [NASDAQ:KPTI]: Analyst Rating and Earnings
Its stock price has been found in the range of 3.92 to 20.09. This is compared to its latest closing price of $16.07.
Pay attention for this company’s financial results, of which the next release is scheduled to happen on Thu 14 May (In 90 Days).
Fundamental Analysis of Karyopharm Therapeutics Inc. [KPTI]
Now let’s turn to look at profitability: with a current Operating Margin for Karyopharm Therapeutics Inc. [KPTI] sitting at -592.97.
This company’s Return on Total Capital is -86.63, and its Return on Invested Capital has reached -62.90%. Its Return on Equity is -114.13, and its Return on Assets is -68.42. These metrics suggest that this Karyopharm Therapeutics Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Karyopharm Therapeutics Inc. [KPTI] has generated a Total Debt to Total Equity ratio of 56.05. Similarly, its Total Debt to Total Capital is 35.92, while its Total Debt to Total Assets stands at 30.09. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -72.16, and its Long-Term Debt to Total Capital is 56.05.
The Enterprise Value to Sales for this firm is now 21.03, and its Total Debt to Enterprise Value stands at 0.33. Karyopharm Therapeutics Inc. [KPTI] has a Price to Book Ratio of 3.11.
Shifting the focus to workforce efficiency, Karyopharm Therapeutics Inc. [KPTI] earns $91,373 for each employee under its payroll. Similarly, this company’s Total Asset Turnover is 0.12. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 7.13 and its Current Ratio is 7.13. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Karyopharm Therapeutics Inc. [KPTI] has 62.61M shares outstanding, amounting to a total market cap of $1.01B. Its stock price has been found in the range of 3.92 to 20.09. At its current price, it has moved down by -23.67% from its 52-week high, and it has moved up 291.20% from its 52-week low.
This stock’s Beta value is currently 2.53, which indicates that it is 5.62% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 38.16. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Karyopharm Therapeutics Inc. [KPTI] a Reliable Buy?
Shares of Karyopharm Therapeutics Inc. [KPTI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.